Why timing the market isn’t luck. It’s a skill that separates smart trades from missed opportunities.

Pfizer acquires Metsera for $47.50 per share upfront plus $22.50 in CVRs, gaining GLP-1 and combo obesity drugs in Phase 2

Precigen just won FDA approval for Papzimeos, the first-ever therapy for recurrent respiratory papillomatosis (RRP)

Roche is acquiring 89bio for $14.50 per share plus up to $6 in CVRs tied to ambitious milestones.

In this article, I break down my personal investment approach with a focus on biotech stocks.